Presenting promising preclinical data at a prestigious symposium like Keystone indicates significant progress in FibroBiologics' research and development. This could lead to increased investor confidence and potentially positive impacts on the stock price in the short term, as it demonstrates advancement towards potential new treatments or therapies.